Image_1_SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC.JPEG
Non-small-cell lung cancer (NSCLC) is the predominant form of lung cancer, and it is regulated by a complex signal transduction network. Single-agent targeted therapy often results in acquired resistance, which leads to treatment failure. In this study, we demonstrated that a combination of the kinase inhibitors trametinib and bosutinib can synergistically suppress the growth of NSCLC by inhibiting both the mitogen-activated protein kinase (MAPK) and proto-oncogene tyrosine-protein kinase (SRC) pathways. The combination was profiled against a panel of 22 NSCLC cell lines, including one erlotinib-resistant cell line, and this combination was found to show synergistic effects against 16 cell lines. NSCLC cell lines (HCC827, HCC827-erlotinib-resistant, and H1650) were treated with trametinib, bosutinib, or a combination of these drugs. The drug combination inhibited colony formation and induced cell apoptosis. A mechanism study showed that the phosphorylation of multiple kinases in the epidermal growth factor receptor (EGFR) signaling pathway in NSCLC was down-regulated. In addition, the combination significantly attenuated tumor growth of HCC827 xenografts with low toxicity. Our findings provide a theoretical basis for further study of the combination of MAPK and SRC pathway inhibitors in NSCLC, especially in the treatment of erlotinib-resistant NSCLC.
History
References
- https://doi.org//10.1056/NEJMra0802714
- https://doi.org//10.3322/caac.20138
- https://doi.org//10.18632/oncotarget.5031
- https://doi.org//10.1016/S1470-2045(11)70393-X
- https://doi.org//10.1056/NEJMoa0810699
- https://doi.org//10.1200/JCO.2012.44.2806
- https://doi.org//10.1007/s10555-012-9391-7
- https://doi.org//10.1158/1078-0432.CCR-12-2246
- https://doi.org//10.1073/pnas.0907325106
- https://doi.org//10.1158/0008-5472.CAN-07-0702
- https://doi.org//10.1158/1078-0432.CCR-17-3697
- https://doi.org//10.1038/onc.2012.25
- https://doi.org//10.18632/oncotarget.4636
- https://doi.org//10.1038/s41419-018-0314-6
- https://doi.org//10.1016/j.canlet.2010.04.020
- https://doi.org//10.1124/pr.58.3.10
- https://doi.org//10.1158/0008-5472.CAN-09-1947
- https://doi.org//10.14670/HH-27.677
- https://doi.org//10.1016/S0304-419X(02)00040-9
- https://doi.org//10.1038/sj.onc.1203912
- https://doi.org//10.1023/A:1023772912750
- https://doi.org//10.1139/o03-077
- https://doi.org//10.1200/JCO.2009.25.4029
- https://doi.org//10.1200/JCO.2010.30.5474
- https://doi.org//10.1097/JTO.0b013e3182161508
- https://doi.org//10.1016/j.cllc.2013.08.001
- https://doi.org//10.1021/jm0102250
- https://doi.org//10.1073/pnas.96.4.1415
- https://doi.org//10.1158/1078-0432.CCR-07-4790
- https://doi.org//10.1158/1078-0432.CCR-10-2200
- https://doi.org//10.1158/1538-7445.AM2011-3585
- https://doi.org//10.1056/NEJMoa1210093
- https://doi.org//10.1056/NEJMoa1203421
- https://doi.org//10.1111/j.1440-1827.2010.02580.x
- https://doi.org//10.1513/pats.200809-107LC
- https://doi.org//10.1016/j.cancergencyto.2010.07.134
- https://doi.org//10.1200/JCO.2005.02.857
- https://doi.org//10.1158/1078-0432.CCR-09-0888
- https://doi.org//10.1002/cncr.27730
- https://doi.org//10.1038/sj.bjc.6602258
- https://doi.org//10.1158/1078-0432.CCR-06-3043
- https://doi.org//10.1002/cncr.27637
- https://doi.org//10.1200/JCO.2009.27.4365
- https://doi.org//10.1093/annonc/mdv072
- https://doi.org//10.1080/14737140.2019.1554440
- https://doi.org//10.1634/theoncologist.2018-0296
- https://doi.org//10.1158/0008-5472.CAN-10-0902
- https://doi.org//10.1158/0008-5472.CAN-09-4524
- https://doi.org//10.3816/CLC.2009.n.039